The vision of the PSORT consortium is to better understand the determinants of response of psoriasis to biologic therapies. By collaboration with our partners from industry we will develop a clinical test to predict response and thereby rationalise and optimise patient care in a cost-effective manner.
The programme of research in the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium aims to use existing knowledge about psoriasis, both clinical and scientificMore Information
Psoriasis is an immune condition, which causes symptoms on the skin and sometimes the joints. Psoriasis is a common skin condition affecting up to 3% of the population of the UK & IrelandMore Information
Please contact us if you would like further information about PSORT using the form below.
The Psoriasis Association is the leading national charity and membership organisation for people affected by psoriasis – patients, families, carers and health professionals- in the UK.More Information
This is the website for the British Association of Dermatologists Biologic Interventions Register. BADBIR is an UK and Eire observational study which seeks to assess the long-term safety of biologic treatments for psoriasis.More Information
The Identification and Management of Psoriasis Associated ComorbidiTy (IMPACT) programme of research is a collaboration between Salford Royal NHS Foundation Trust, the University of Manchester, and the Psoriasis Association. IMPACT is funded by the National Institute for Health Research (NIHR).
Biomarkers of Systemic Treatment Outcomes in Psoriasis study (BSTOP) is closely aligned to BADBIR and is an integral part of PSORT. It seeks to identify and characterize biomarkers of response to systemic and biologic treatments for psoriasis.More Information
Internationally competitive expertise exists across the consortium between investigators and collaborators in all of the scientific disciplines required to successfully deliver the PSORT programme.
We have developed an extensive network of pharmaceutical and diagnostic company partners who bring specific expertise and resources to the programme.